^
    Back
    Association details:
    Biomarker:KIT mutation
    Cancer:Melanoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma

    Excerpt:
    ...- Tumor blocks or slides must be available of either primary or metastatic tumor site for c-kit mutation testing...
    Trial ID:
    NCT00577382
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Sunitinib therapy for melanoma patients with KIT mutations

    Excerpt:
    Of the 4 evaluable patients with KIT mutations, 1 had a complete remission for 15 months and 2 had partial responses (1- and 7-month duration).
    DOI:
    10.1158/1078-0432.CCR-11-1987